Wai L Liu

Efficacy and safety of the histamine H4 receptor antagonist ZPL‐3893787 in patients with atopic dermatitis

I. Osterloh, M. Yeadon, G. Layton, 2019, The Journal of allergy and clinical immunology.

Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2α for the Treatment of Asthma

M. Cazzola, J. D. Clark, M. Yeadon, 2012, Journal of Pharmacology and Experimental Therapeutics.

Gene expression and immunolocalization of 15-lipoxygenase isozymes in the airway mucosa of smokers with chronic bronchitis.

R. Pauwels, M. Yeadon, J. Kips, 2002, American journal of respiratory cell and molecular biology.

The discovery and profile of PF-0868087, a CNS-sparing histamine H3 receptor antagonist for the treatment of allergic rhinitis

Tanya L Hay, M. Yeadon, C. Mowbray, 2012 .

A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults

A. Nikkels, M. Yeadon, G. Layton, 2016 .

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

Rob Leurs, Holger Stark, H. Haas, 2015, Pharmacological Reviews.

CNS-Sparing Histamine H3 Receptor Antagonist as a Candidate to Prevent the Diabetes-Associated Gastrointestinal Symptoms

A. Pini, P. Chazot, P. Nardini, 2022, Biomolecules.

Histamine H4 receptor antagonists for the treatment of inflammatory disorders.

Wai L Liu, 2014, Drug discovery today.

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

H. Haas, R. Thurmond, R. Leurs, 2015, Pharmacological Reviews.